Jun 5, 2026
Multiple states are now considering legislation to ban the herbicide
Written by Doc Irish | June 2, 2026
There are moments when a disease stops being only a medical story and becomes a public trust story. A prevention story. A question of whether the people who know enough to act will do so in time. I think Parkinson’s disease is having one of those moments now.
For years, many of us living with Parkinson’s have been told some version of the same unsatisfying sentence: We do not know what caused it. Parkinson’s is complicated. Genes, aging, and biology matter. No one should pretend that one chemical explains every diagnosis. But uncertainty is not ignorance. And it is certainly not an excuse for paralysis.
The Parkinson’s Foundation says genetics contribute to about 10% to 15% of Parkinson’s cases, while environmental factors, including pesticide exposure, can influence risk. That leaves millions of us living in the gray zone between “we do not know” and “we should have known enough to do more.”
Paraquat sits squarely in that gray zone. This highly toxic herbicide has been linked in multiple studies and advocacy campaigns to increased Parkinson’s risk. Its use is already banned in more than 70 countries, including China, where it is still manufactured and exported, yet remains legal in the United States. Advocates, scientists, patients, and families have warned about it. Still, the chemical remains in use.
Jun 4, 2026
Experimental treatment's safety, tolerability will be assessed
Written by Andrea Lobo | June 2, 2026
- A Phase 2a trial of Jotrol is enrolling Parkinson's disease patients.
- Jotrol aims to reduce brain inflammation and oxidative stress.
- The trial will assess Jotrol's safety, tolerability, and effects on motor/non-motor symptoms.
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced.
The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in the U.S.: Georgetown University MedStar Hospital in Washington, DC; Montgomery and Franklin Square MedStar Hospitals in Maryland; and MedStar McLean Clinic in Virginia.
The trial, which will assess the treatment’s safety, tolerability, and pharmacological properties, is expected to be completed in the first half of 2027.
“With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community,” Christer Rosén, Jupiter’s CEO, said in a company press release.
Jotrol preserved motor function in mouse model
Parkinson’s is marked by the loss of brain cells called dopaminergic neurons, which produce dopamine, a signaling molecule involved in motor control. Lack of dopamine signaling leads to the disease’s symptoms, including movement problems and cognitive issues.
While the exact causes of Parkinson’s aren’t fully known, research suggests that excessive brain inflammation and oxidative stress, a type of cellular damage, help drive nerve cell damage and contribute to disease progression.
Resveratrol is a compound found in certain plants, including grapes, with anti-inflammatory and antioxidant properties, meaning it can reduce inflammation and oxidative stress. However, its use has been limited due to digestive issues when taken orally at high doses.
Jun 3, 2026
By Simon Spichak, MSc / Published On: May 11, 2026
“Originally published on Being Patient, an editorially independent news site covering the latest research on Alzheimer’s disease and brain health.”
A new study finds that the protein alpha-synuclein may accelerate harmful tau buildup in women’s brains, offering new insight into disease progression.
Alzheimer’s is defined by beta-amyloid plaques which build up between brain cells and tau tangles that slowly destroy them from the inside. But many people with the disease also accumulate other toxic proteins within the brain.
Alpha-synuclein, a protein that misfolds across Parkinson’s and dementia with Lewy bodies, is also commonly found clumping up in the brains of around half of Alzheimer’s cases.
Until recently, scientists could only measure alpha-synuclein during an autopsy. Using new cerebrospinal fluid tests, researchers from the Mayo Clinic could detect these misfolded proteins in living study participants.
Their latest research, published in JAMA Network Open adds sex to the story. The presence of misfolded alpha-synuclein was linked with 20-fold faster accumulation of tau tangles in women but not in men.
“This finding may explain why some women experience more aggressive dementia progression,” said lead author Elijah Mak of the Mayo Clinic. “Although we’d like to emphasize that more research is needed with larger sample sizes.”
Jun 2, 2026
Many caregivers experience a sense of loss for the person they were before
Written by Jamie Askari | May 26, 2026
My husband, Arman, who has early-onset Parkinson’s disease, and I don’t get to the movies very often. Instead, we prefer to wait and stream films from the comfort of home. But when the movie “Wicked” was released in theaters in November 2024, there was no way our small TV with its basic speakers was going to cut it. So we ventured out to the theater.
Since it was Thanksgiving week, two of our children were home to see it with us, which came with the added bonus of helping us at the theater. While it was wonderful to share this movie experience with them, it was also great to have the help, as places like movie theaters have become a significant challenge for us, so we rarely go. Navigating the crowds can be overwhelming, and seating is often complicated for those who use assistive devices, so having our children along to assist made a world of difference.
The music, the sets, and the costumes were as perfect as I had imagined. It was beautiful to see Marissa Bode, the actress who played Nessarose, as she is the first actor to use a wheelchair in real life to portray this character.
Although the movie was a few years back, I still often listen to all of the music from it. As I was cooking dinner the other night, the song “For Good” came up on my playlist. It’s the kind of song you want to sing at the top of your lungs, no matter how terrible you sound! As I was chopping vegetables and belting out the song, I thought about its lyrics and realized there are many parallels to my role as Arman’s caregiver.
The line “I have been changed for good” hits close to home, as I have actually changed immensely since my husband’s diagnosis. There is a past version of me that got left behind somewhere along my caregiving journey. Bits and pieces of me slowly shed as I evolved into the person I am today. That is a person I don’t even remember anymore.
What I do remember is that she slept peacefully through the night, lived without constant fear, walked into rooms without scanning for fall risks, and didn’t hold her breath as she waited for the next crisis. She was carefree, calm, and easygoing, with a lightness about her. She was able to relax and enjoy the moment. I hope that my children remember her, especially on the days that I don’t particularly like the new version of me.
Jun 1, 2026
iRS platform is being developed as a possible early detection tool
Written by Andrea Lobo | May 28, 2026
- German researchers developed an iRS blood test that may help support earlier Parkinson’s detection.
- The test is designed to identify misfolded alpha-synuclein, a protein linked to Parkinson’s disease.
- The technology could one day support earlier diagnosis and treatment decisions, but regulatory approval is needed before public use.
A team of researchers in Germany has developed an immuno-infrared sensor (iRS) designed to detect misfolded alpha-synuclein, a protein linked to Parkinson’s disease, in body fluids including blood and the fluid that surrounds the brain and spinal cord. The researchers say the technology could one day support earlier diagnosis, potentially before symptoms appear.
The team is led by Klaus Gerwert, PhD, professor at Ruhr University Bochum and founder and CEO of Betasense. The company is using iRS in clinical studies, and studies have shown the platform can detect disease-related alpha-synuclein misfolding in body fluids.
According to Grischa Gerwert, the paper’s first author, this technology may have broad applications for analyzing a wide variety of molecules in complex solutions. “This method holds promise for broad clinical application and population-wide screening in the future,” Grischa said in a university news story.
The paper, “An Immuno-Infrared Sensor Detects Preclinical Alzheimer’s and Parkinson’s Disease by Protein Misfolding,” was published in The Journal of Physical Chemistry B.
Why alpha-synuclein matters in Parkinson’s
In Parkinson’s, misfolded alpha-synuclein forms oligomers – early clumps of the protein – that can aggregate into fibrils deposited in Lewy bodies. Alpha-synuclein clumps are thought to contribute to nerve cell damage linked to the disease’s symptoms. Misfolded forms of alpha-synuclein also can be detected in body fluids, including blood and cerebrospinal fluid, or CSF, the liquid that surrounds the brain and spinal cord.
Diagnosis is largely based on motor symptoms, including slowed movement, rigidity, and tremor, which usually appear after substantial nerve cell damage. While therapies can ease Parkinson’s symptoms, earlier diagnosis could help support earlier treatment and future therapeutic strategies.
“Because of this, there is a broad consensus in the scientific community that therapy needs to begin much sooner, even before the typical insoluble protein deposits form in the brain,” Klaus Gerwert said.
iRS was developed using specific antibodies attached to the sensor with a patented surface chemistry to isolate misfolded proteins, including alpha-synuclein, from body fluids. It allows measurement of the degree of alpha-synuclein misfolding, addressing the need for a noninvasive, cost-effective blood test.
The sensor can distinguish alpha-synuclein monomers, oligomers, and fibrils based on where each form absorbs infrared light. During the alpha-synuclein aggregation process, from monomers to oligomers and fibrils, this infrared signal shifts, indicating increasing protein misfolding.
Recent Comments